On this page ▾
The market expects much less from Alkem Labs than it has delivered before.
At today’s share price, buyers are assuming Alkem Labs grows about 3% a year, forever. Over the last ten years it actually grew about 9% a year. That is a big step down from its own record. Either the market can see a problem that the published accounts do not show yet, or it is expecting a slowdown that has not happened.
- How it is valued: Discounted cash flow.
- What the price assumes: 3% growth, against 9% the model takes from its own record.
- Ten-year record: Between FY2018 and FY2026, Alkem Labs' revenue went from ₹6,431 crore to ₹14,712 crore — it compounded at about 11% a year over 8 years.
- Biggest swing factor: India acute market. Main risk: Price controls.
01Antibiotics, antacids and US generics
Alkem Laboratories, founded in Mumbai by Samprada Singh's family, is one of India's largest drugmakers by domestic sales, leading in acute treatments such as antibiotics, pain relief and gastro medicines, with brands like Clavam, Pan and Taxim.
It also sells generics in the US and is building chronic-therapy, medical-device and contract-manufacturing businesses.
02What the market is assuming
Work backwards from today's share price and you can see what buyers are quietly taking for granted. Here is the growth that price implies for Alkem Labs, next to what the model assumes from the company's own record.
The further apart these two numbers are, the bigger the bet a buyer at today's price is making.
03Alkem Labs' record, in plain numbers
Between FY2018 and FY2026, Alkem Labs' revenue went from ₹6,431 crore to ₹14,712 crore — it compounded at about 11% a year over 8 years. Net profit grew from ₹638 crore to ₹2,351 crore, about 18% a year — faster than revenue, so margins widened. In FY2026 it kept 16.0% of revenue as net profit — against a low of 8.7% in FY2023 and a high of 17.1% in FY2025. The latest year added 13.5% to revenue, close to its own long-run pace. FY2021 is missing from the filed series used here, so that year is left out rather than estimated.
Revenue and earnings per share in ₹, return on equity and leverage as ratios — all from the filed statements.
Revenue and net profit by year (₹ crore)
| Year | Revenue | Net profit | Margin |
|---|---|---|---|
| FY2018 | 6,431 | 638 | 9.9% |
| FY2019 | 7,357 | 774 | 10.5% |
| FY2020 | 8,344 | 1,149 | 13.8% |
| FY2022 | 10,634 | 1,680 | 15.8% |
| FY2023 | 11,599 | 1,007 | 8.7% |
| FY2024 | 12,668 | 1,811 | 14.3% |
| FY2025 | 12,965 | 2,215 | 17.1% |
| FY2026 | 14,712 | 2,351 | 16.0% |
04How Alkem Labs gets valued — and why
Discounted cash flowThis business is valued on the cash it is expected to generate, discounted back at its cost of capital — with growth taken from its own ten-year record rather than from guidance.
05What decides Alkem Labs' value
India acute market
Seasonal infections drive demand.
Chronic therapies
Growth in diabetes and heart care lifts margins.
US generics
Launches offset price erosion.
Cost control
Margins have improved.
06What could go wrong
- Price controls. Many acute drugs fall under price caps.
- Seasonality. Mild infection seasons slow sales.
- US pricing. Generic price erosion.
07What the full Alkem valuation shows
Sign in free to see the complete Alkem Labs valuation
- ✓Fair value per share — from a ten-year discounted cash flow, every step shown
- ✓The Workbench — change revenue growth, the discount rate or terminal growth and watch Alkem's value move
- ✓Bull, base and bear cases — and exactly which assumptions move between them
- ✓Peer comparison — against Mankind Pharma, Torrent Pharma and Sun Pharma
- ✓Downloadable report — the full write-up, yours to keep
08Questions people ask about Alkem Labs
What are Alkem's best-known brands?
Clavam, Pan, Pan-D and Taxim.
Is Alkem mainly an India business?
Yes, though it also sells generics in the US.
Why do price controls matter for Alkem?
Many acute medicines fall under India's drug-price controls.
Is Alkem Labs overvalued?
At ₹5,114 the market is pricing in roughly 3% sustained growth, against the ~9% its own record supports. That is less than it has delivered — on these numbers the market is asking the business for less than its own record, which usually means it doubts the record repeats.
What is the intrinsic value of Alkem Labs?
It is computed from the filed financial statements using the method that fits this business (discounted cash flow), with every assumption shown alongside the result. The per-share figure and the full working are in the report.
How much debt does Alkem Labs carry?
Debt to equity stands at 0.03, against 0.01 at the start of the period — the balance sheet is a core input to the cost of capital used here.